{"id":424521,"date":"2021-01-29T08:03:32","date_gmt":"2021-01-29T13:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=424521"},"modified":"2021-01-29T08:03:32","modified_gmt":"2021-01-29T13:03:32","slug":"vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/","title":{"rendered":"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts"},"content":{"rendered":"<h2>\nInternationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">HIGHLANDS RANCH, Colo., Jan.  29, 2021  (GLOBE NEWSWIRE) &#8212; <strong>Vivos Therapeutics, Inc. (\u201cVivos\u201d) (NASDAQ: VVOS)<\/strong>, a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced that the Company has established a Clinical Advisory Board to further drive adoption and growth of its next-generation treatments for OSA, of which 1 billion people suffer from globally.<\/p>\n<p align=\"justify\">Members of Vivos\u2019 Clinical Advisory Board currently include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Clete A. Kushida, MD, PhD \u2013 Neurologist, sleep specialist, Stanford Sleep Medicine Center\u2019s Division Chief and Medical Director, World Sleep Society\u2019s founding President<\/li>\n<li style=\"text-align:justify\">Edward Zuckerberg, DDS \u2013 Nationally recognized key opinion leader in the advanced dentistry field<\/li>\n<li style=\"text-align:justify\">Michael Gelb, DDS, MS \u2013 American Board of Orofacial Pain Diplomate, NYU College of Dentistry Clinical Professor, American Academy of Physiological Medicine and Dentistry Co-Founder<\/li>\n<li style=\"text-align:justify\">Manisha Witmans, MD, FAASM \u2013 Board-certified sleep specialist and pediatric pulmonologist, Associate Clinical Professor at the University of Alberta<\/li>\n<li style=\"text-align:justify\">Tammarie Heit, DDS, MICCMO, RN \u2013 Completed mastership program at the International College of Craniomandibular Orthopedics, established private practice focused on craniofacial sleep medicine and dentistry<\/li>\n<li>Jon Caulfield, DDS \u2013 American Sleep and Breathing Academy Diplomate; established private practice specializing in airway, sleep and TMJ disorders<\/li>\n<\/ul>\n<p align=\"justify\">\u201cIn forming Vivos\u2019 new Clinical Advisory Board, we sought out the world\u2019s leading minds in the sleep medicine and dentistry fields,\u201d said Kirk Huntsman, Vivos\u2019 Chairman and Chief Executive Officer. \u201cEach member holds the highest level of credentials and brings decades of combined experience to the table. They are charged with ensuring that our Vivos System technology remains at the forefront of treatment for patients continuing to suffer from sleep apnea across the U.S.\u201d<\/p>\n<p align=\"start\">\n        <strong>About Vivos Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient\u2019s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.<\/p>\n<p align=\"justify\">For more information, visit www.vivoslife.com.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as \u201cmay\u201d, \u201cshould\u201d, \u201cexpects\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cbelieves\u201d, \u201canticipates\u201d, \u201chopes\u201d, \u201cestimates\u201d and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos\u2019 control. Actual results (including, without limitation, the impact of the Clinical Advisory Board described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos\u2019 filings with the Securities and Exchange Commission (\u201cSEC\u201d). Vivos\u2019 filings can be obtained free of charge on the SEC&#8217;s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos&#8217; expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/> Edward Loew <br \/> Investor Relations Officer <br \/> (602) 903-0095 <br \/> ed@vivoslife.com<\/p>\n<p align=\"justify\">\n        <strong>Media Relations Contact:<\/strong><br \/>\n        <br \/> Caitlin Kasunich \/ Jenny Robles <br \/> KCSA Strategic Communications <br \/> (212) 896-1241 \/ (917) 420-1444 <br \/> ckasunich@kcsa.com \/ jrobles@kcsa.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7da48022-fbce-4e4e-97af-8061fa70dc08\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success HIGHLANDS RANCH, Colo., Jan. 29, 2021 (GLOBE NEWSWIRE) &#8212; Vivos Therapeutics, Inc. (\u201cVivos\u201d) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced that the Company has established a Clinical Advisory Board to further drive adoption and growth of its next-generation treatments for OSA, of which 1 billion people suffer from globally. Members of Vivos\u2019 Clinical Advisory Board currently include: Clete A. Kushida, MD, PhD \u2013 Neurologist, sleep specialist, Stanford Sleep Medicine Center\u2019s Division Chief and Medical Director, World Sleep Society\u2019s founding President Edward Zuckerberg, DDS &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-424521","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success HIGHLANDS RANCH, Colo., Jan. 29, 2021 (GLOBE NEWSWIRE) &#8212; Vivos Therapeutics, Inc. (\u201cVivos\u201d) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced that the Company has established a Clinical Advisory Board to further drive adoption and growth of its next-generation treatments for OSA, of which 1 billion people suffer from globally. Members of Vivos\u2019 Clinical Advisory Board currently include: Clete A. Kushida, MD, PhD \u2013 Neurologist, sleep specialist, Stanford Sleep Medicine Center\u2019s Division Chief and Medical Director, World Sleep Society\u2019s founding President Edward Zuckerberg, DDS &hellip; Continue reading &quot;Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-29T13:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts\",\"datePublished\":\"2021-01-29T13:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/\"},\"wordCount\":737,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/\",\"name\":\"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=\",\"datePublished\":\"2021-01-29T13:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/","og_locale":"en_US","og_type":"article","og_title":"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts - Market Newsdesk","og_description":"Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success HIGHLANDS RANCH, Colo., Jan. 29, 2021 (GLOBE NEWSWIRE) &#8212; Vivos Therapeutics, Inc. (\u201cVivos\u201d) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced that the Company has established a Clinical Advisory Board to further drive adoption and growth of its next-generation treatments for OSA, of which 1 billion people suffer from globally. Members of Vivos\u2019 Clinical Advisory Board currently include: Clete A. Kushida, MD, PhD \u2013 Neurologist, sleep specialist, Stanford Sleep Medicine Center\u2019s Division Chief and Medical Director, World Sleep Society\u2019s founding President Edward Zuckerberg, DDS &hellip; Continue reading \"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-29T13:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts","datePublished":"2021-01-29T13:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/"},"wordCount":737,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/","name":"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=","datePublished":"2021-01-29T13:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzgyMiMzOTUxMTE4IzIyMDU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-forms-clinical-advisory-board-to-drive-further-growth-of-next-generation-obstructive-sleep-apnea-treatment-efforts\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/424521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=424521"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/424521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=424521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=424521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=424521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}